Treatment with anti-erbb2 antibodies
AssigneeGenentech, Inc.
InventorMARK SLIWKOWSKI
Life of this patent
Estimating the term…
Abstract
The present application describes methods for treating cancer with anti-ErbB2 antibodies, such as anti-ErbB2 antibodies that block ligand activation of an ErbB receptor.
Claims8
A method of treating cancer that expresses ErbB2 comprising administering to a human a therapeutically effective amount of an antibody which binds ErbB2 and a therapeutically effective amount of a second drug, wherein the second drug is a tyrosine kinase inhibitor, wherein the antibody and the second drug are administered separately or in combination, and in either order, and wherein the cancer is not characterized by overexpression of ErbB2.
A method of treating cancer that expresses ErbB2 comprising administering to a human a therapeutically effective amount of humanized 2C4 antibody and a therapeutically effective amount of GW2016 (lapatinib), and wherein the antibody and the GW2016 are administered separately or in combination, and in either order.
A method of treating cancer that overexpresses epidermal growth factor (EGF) or transforming growth factor alpha (TGF-α) comprising administering to a human a therapeutically effective amount of humanized 2C4 antibody and a therapeutically effective amount of a tyrosine kinase inhibitor, and wherein the antibody and the tyrosine kinase inhibitor are administered separately or in combination, and in either order.
Dependencies are inferred from the claim text.